$10.75
7.05% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US71716E1055
Symbol
PHAR

Pharming Group N.V. - ADR Stock price

$10.75
+0.75 7.50% 1M
+1.77 19.68% 6M
+0.69 6.81% YTD
+2.15 25.05% 1Y
-5.95 35.63% 5Y
-5.95 35.63% 10Y
-5.95 35.63% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.81 7.05%
ISIN
US71716E1055
Symbol
PHAR
Sector
Industry

Key metrics

Market capitalization $797.51m
Enterprise Value $809.38m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 159.33
EV/Sales (TTM) EV/Sales 2.52
P/S ratio (TTM) P/S ratio 2.49
P/B ratio (TTM) P/B ratio 34.24
Revenue growth (TTM) Revenue growth 24.13%
Revenue (TTM) Revenue $320.71m
EBIT (operating result TTM) EBIT $8.45m
Free Cash Flow (TTM) Free Cash Flow $5.08m
Cash position $107.27m
EPS (TTM) EPS $-0.02
P/S forward 2.49
EV/Sales forward 2.53
Short interest 0.01%
Show more

Is Pharming Group N.V. - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Pharming Group N.V. - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Pharming Group N.V. - ADR forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Pharming Group N.V. - ADR forecast:

Buy
100%

Financial data from Pharming Group N.V. - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
321 321
24% 24%
100%
- Direct Costs 35 35
20% 20%
11%
285 285
25% 25%
89%
- Selling and Administrative Expenses 195 195
4% 4%
61%
- Research and Development Expense 84 84
16% 16%
26%
21 21
84% 84%
7%
- Depreciation and Amortization 13 13
35% 35%
4%
EBIT (Operating Income) EBIT 8.45 8.45
205% 205%
3%
Net Profit -14 -14
31% 31%
-4%

In millions USD.

Don't miss a Thing! We will send you all news about Pharming Group N.V. - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pharming Group N.V. - ADR Stock News

Neutral
GlobeNewsWire
3 days ago
Leiden, the Netherlands, June 11, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved.
Neutral
Seeking Alpha
about one month ago
Pharming Group N.V. (NASDAQ:PHAR ) Q1 2025 Earnings Conference Call May 8, 2025 7:30 AM ET Company Participants Fabrice Chouraqui – CEO Stephen Toor – CCO Anurag Relan - Chief Medical Officer Jeroen Wakkerman - CFO Conference Call Participants Jeff Jones – Oppenheimer Joe Pantginis - H.C.
Neutral
Seeking Alpha
3 months ago
Pharming Group N.V. (NASDAQ:PHAR ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Fabrice Chouraqui - CEO Stephen Toor - CCO Anurag Relan - Chief Medical Officer Jeroen Wakkerman - CFO Conference Call Participants Jeff Jones – Oppenheimer Ben Jackson – Jefferies Alistair Campbell - RBC Capital Markets Joe Pantginis - H.C.
More Pharming Group N.V. - ADR News

Company Profile

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.

Head office Netherlands
CEO Fabrice Chouraqui
Employees 404
Founded 1988
Website www.pharming.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today